Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17408-13. Epub 2006 Nov 7.

2.

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ.

J Clin Oncol. 2004 Jun 1;22(11):2108-21.

PMID:
15169797
3.

Assays for proteasome inhibition.

Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES.

Methods Mol Med. 2003;85:163-72. Review. No abstract available.

PMID:
12710207
4.

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL.

J Clin Oncol. 2002 Nov 15;20(22):4420-7.

PMID:
12431963
5.

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC.

Cancer Res. 2002 Sep 1;62(17):4996-5000.

6.

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR.

Clin Cancer Res. 2002 Aug;8(8):2505-11.

7.

Proteasome inhibition measurements: clinical application.

Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ.

Clin Chem. 2000 May;46(5):673-83.

8.

Proteasome inhibition: A novel mechanism to combat asthma.

Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J.

J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):294-300.

PMID:
10452747
9.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ.

Cancer Res. 1999 Jun 1;59(11):2615-22.

Supplemental Content

Support Center